Hereditary Disease Foundation

The Hereditary Disease Foundation (HDF) is a United States-based biomedical research foundation focused on accelerating the understanding and treatment of inherited neurological and genetic disorders. Its work is particularly associated with Huntington's disease, a progressive inherited neurodegenerative disorder, and with the development of research methods that helped make the disease one of the earliest genetic disorders to be investigated through modern gene mapping. The foundation was established in 1968 by Milton Wexler after Huntington's disease affected his wife's family. Rather than operating primarily as a patient-support organization, HDF was created to coordinate scientists, provide research support, and encourage collaboration across laboratories. Its approach emphasized basic biomedical research as the foundation for future diagnostics and therapies. The organization became known for bringing together researchers from different disciplines and institutions around difficult genetic questions that individual laboratories could not easily solve alone. A major turning point came from an HDF workshop in 1979, where researchers proposed mapping the human genome and identifying a genetic marker associated with Huntington's disease. HDF subsequently worked with the National Institute of Neurological Disorders and Stroke and Nancy Wexler, Milton Wexler's daughter, on the United States–Venezuela Huntington's Disease Collaborative Research Project. The project studied a large Venezuelan family group, or kindred, in which Huntington's disease occurred with unusually high frequency. The availability of numerous related participants enabled researchers to compare inherited genetic material and disease status across generations. In 1983, the collaboration identified a marker linked to the Huntington's disease gene. During the following decade, continued research involving HDF helped lead to the identification of the gene itself, known as huntingtin. The achievement was important not only for Huntington's disease research but also for medical genetics more broadly. Techniques developed during the search contributed to the development of the Human Genome Project and influenced approaches to locating other disease-associated genes. The work also helped establish concepts and practical frameworks relevant to genetic testing, counseling, and the eventual development of genetically targeted therapies. HDF's role has therefore extended beyond direct funding. It has acted as a convening and coordinating institution, supporting scientific meetings, collaborative projects, and the circulation of knowledge among researchers. Its historical identity is closely tied to Huntington's disease, although its founding mission addressed hereditary illness more generally. In 2025, the organization announced that it had officially changed its name to the Huntington's Disease Foundation while retaining the HDF abbreviation. The renaming signaled a more explicit focus on Huntington's disease while preserving continuity with the foundation's established scientific identity. The foundation remains an active research-oriented organization. Its principal contribution is the support and coordination of scientific work intended to clarify the causes of inherited disease and translate genetic discoveries into diagnostics and treatments. It is not a listed company, does not have publicly traded shares, and does not operate as a conventional consumer brand.

Milton Wexler founded the Hereditary Disease Foundation in 1968 after Huntington's disease affected his wife's family. The organization was created to pursue cures for hereditary disorders by coordinating researchers and supporting basic biomedical investigation. Its model differed from that of a conventional disease charity: HDF concentrated on building the scientific infrastructure needed to understand genetic causes and develop future therapies. HDF became especially influential in Huntington's disease research. At a foundation workshop in 1979, participants advanced the idea of mapping the human genome and searching for a genetic marker linked to Huntington's disease. This goal required large-scale family studies and cooperation among laboratories, public institutions, and clinicians. HDF joined with the National Institute of Neurological Disorders and Stroke and Nancy Wexler, Milton Wexler's daughter, to organize the United States–Venezuela Huntington's Disease Collaborative Research Project. The project examined a Venezuelan kindred with an unusually high prevalence of Huntington's disease. Because the study included many related individuals across generations, researchers could compare inherited genetic patterns with the appearance of disease. In 1983, the project produced a marker associated with the Huntington's disease gene. The result was a landmark in human genetics because it demonstrated that a disease gene could be approached through linkage mapping even before the gene itself had been isolated. Over the next decade, further work involving HDF helped researchers identify the gene responsible for Huntington's disease, called huntingtin. The discovery was among the earliest successful identifications of a human disease gene and had consequences well beyond Huntington's disease. Methods developed during the search informed work associated with the Human Genome Project and helped shape research strategies for other inherited illnesses. The discovery also contributed to the scientific and ethical foundations of genetic testing, genetic counseling, and the search for treatments directed at specific genetic mechanisms. Throughout its history, HDF has functioned as a convener as well as a funder. It has promoted exchanges among scientists, supported collaborative research, and helped direct attention toward difficult problems in inherited neurological disease. Its historical mission covered hereditary disorders generally, but Huntington's disease became the central focus of its public and scientific identity. In 2025, the foundation announced an official name change from the Hereditary Disease Foundation to the Huntington's Disease Foundation. The organization retained the abbreviation HDF. The change clarified its primary disease focus while maintaining continuity with the name under which its research legacy had developed. Nancy Wexler is identified as the foundation's president. The available reference material does not establish a specific headquarters address, detailed funding figures, a complete executive history, or a comprehensive list of current programs.

• 2025

  Official name changed to Huntington's Disease Foundation

  [2]Hereditary Disease Foundation official websitehdfoundation.org

  The foundation announced a formal name change while retaining the HDF abbreviation.

• 1990

  Huntingtin gene identified during the following decade

  [1]Hereditary Disease Foundationen.wikipedia.org

  Further research involving HDF led to identification of the Huntington's disease gene, known as huntingtin, during the decade after the 1983 marker discovery.

• 1983

  Huntington's disease genetic marker identified

  [1]Hereditary Disease Foundationen.wikipedia.org

  The United States–Venezuela collaborative research effort identified a marker linked to the gene responsible for Huntington's disease.

• 1979

  Genome-mapping strategy proposed

  [1]Hereditary Disease Foundationen.wikipedia.org

  An HDF workshop helped advance the proposal to map the human genome and locate a genetic marker for Huntington's disease.

• 1968

  Foundation established

  [1]Hereditary Disease Foundationen.wikipedia.org

  Milton Wexler founded the Hereditary Disease Foundation after Huntington's disease affected his wife's family, with a mission centered on accelerating research into inherited diseases.

A research-focused nonprofit positioned as a catalyst for collaborative biomedical discovery in Huntington's disease and other inherited disorders.

• Research funding and coordination · 1968

  Biomedical research support

  HDF supports and coordinates basic biomedical research intended to clarify the genetic and biological mechanisms of inherited disorders. Its historical work has emphasized collaboration among scientists and the development of methods that can eventually support diagnosis and treatment. The foundation is best understood as a research catalyst rather than a producer of commercial medical products.

• Genetic disease research · 1979

  Huntington's disease research collaboration

  The foundation's most prominent research initiative was its collaboration with the National Institute of Neurological Disorders and Stroke and Nancy Wexler on the United States–Venezuela Huntington's Disease Collaborative Research Project. The study used a large Venezuelan kindred with a high prevalence of Huntington's disease to identify inherited markers and advance the search for the huntingtin gene.

• 2025

  Adopted the Huntington's Disease Foundation nameStrategy

  Background

  Although the foundation was established to address hereditary diseases broadly, its scientific history and public identity became strongly associated with Huntington's disease.

  Action taken

  The organization officially changed its name to the Huntington's Disease Foundation while retaining the HDF abbreviation.

  Aftermath

  The new name makes the foundation's principal disease focus more explicit while preserving continuity with its established abbreviation and research legacy.

  Source

1. 1Hereditary Disease Foundationen.wikipedia.org
2. 2Hereditary Disease Foundation official websitehdfoundation.org